Regulatory compliance is a critical aspect of pharmaceutical product lifecycle management. When making post-approval changes in topical formulations, selecting the appropriate FDA submission pathway—CBE-30 (Changes Being Effected in 30 Days) or PAS (Prior Approval Supplement)—ensures compliance while maintaining business continuity. Understanding when to file CBE-30 vs. PAS can significantly impact timelines, regulatory approvals, and market…
Formulating effective topical products is a complex process that requires balancing efficacy, stability, and patient compliance. Here are some common challenges and practical solutions: Poor Drug Penetration Instability of Active Ingredients Phase Separation in Emulsions Grittiness or Texture Issues Preservative System Failure Inconsistent Spreadability & Feel Successful topical formulations require a deep understanding of formulation…
In topical pharmaceutical development, achieving batch-to-batch consistency, therapeutic efficacy, and regulatory compliance requires a Quality by Design (QbD) framework. A well-defined design space based on Critical Material Attributes (CMAs), Critical Process Parameters (CPPs), and Critical Quality Attributes (CQAs) ensures an optimized, scalable, and reproducible formulation. Identifying CMAs in Topical Formulations API Attributes: Excipient Functionality: Defining…
A Biowaiver for a topical dosage form refers to regulatory approval for marketing a generic topical product without conducting in vivo bioequivalence (BE) studies. Instead, equivalence is demonstrated using in vitro methods and other scientific justifications. Key Considerations for Biowaiver of Topical Dosage Forms Regulatory agencies such as USFDA, EMA, and WHO provide guidelines for…
End of content
End of content
